Literature DB >> 25113439

Regulatory T cells with CD62L or TNFR2 expression in young type 1 diabetic patients: relation to inflammation, glycemic control and micro-vascular complications.

Mona H El-Samahy1, Amira A M Adly1, Eman A Ismail2, Nouran Yousef Salah1.   

Abstract

BACKGROUND: Alteration of regulatory T cells (Tregs) may contribute to ineffective suppression of proinflammatory cytokines in type 1 diabetes. AIM: We determined the percentage of Tregs expressing CD62L or tumor necrosis factor receptor type 2 (TNFR2) in 70 young type 1 diabetic patients compared with 30 controls and assessed their relation to inflammation, glycemic control and micro-vascular complications.
METHODS: High-sensitivity C-reactive protein (hs-CRP), hemoglobin A1c (HbA1c), tumor necrosis factor alpha (TNF-α) and interleukin-10 (IL-10) were assessed with flow cytometric analysis of Tregs, Tregs expressing CD62L or TNFR2.
RESULTS: The percentage of CD4(+)CD25(high) T cells and CD4(+)CD25(high)CD62L(high) cells were significantly decreased while CD4(+)CD25(high)TNFR2(+) T cells were elevated in patients with micro-vascular complications than those without and controls (p<0.001). ROC curve revealed that the cutoff values of Tregs, Tregs expressing CD62L and Tregs expressing TNFR2 (7.46%, 24.2% and 91.9%, respectively) could detect micro-vascular complications. Significant negative correlations were observed between Tregs expressing CD62L and disease duration, FBG, HbA1c, urinary albumin excretion and hs-CRP, whereas, positive correlations were found between Tregs expressing TNFR2 and these variables (p<0.05). TNF-α was significantly increased while IL-10 was decreased among patients with micro-vascular complications than those without (p<0.05).
CONCLUSIONS: Alteration in the frequency of Tregs and Tregs expressing CD62L or TNFR2 in type 1 diabetes is associated with increased inflammation, poor glycemic control and risk of micro-vascular complications.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD62L; Micro-vascular complications; TNFR2; Tregs; Type 1 diabetes

Mesh:

Substances:

Year:  2014        PMID: 25113439     DOI: 10.1016/j.jdiacomp.2014.07.004

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  5 in total

1.  Circulating L-selectin expressing-T cell subsets correlate with the severity of Foxp3 deficiency autoimmune disease.

Authors:  Yuying Liu; Thomas K Hoang; Ting Wang; Baokun He; Dat Q Tran; Jain Zhou; Nina Tatevian; J Marc Rhoads
Journal:  Int J Clin Exp Pathol       Date:  2016-02-15

2.  Not Only Glycaemic But Also Other Metabolic Factors Affect T Regulatory Cell Counts and Proinflammatory Cytokine Levels in Women with Type 1 Diabetes.

Authors:  Katerina Stechova; Jana Sklenarova-Labikova; Tereza Kratzerova; Pavlina Pithova; Dominik Filipp
Journal:  J Diabetes Res       Date:  2017-05-03       Impact factor: 4.011

Review 3.  The change of serum tumor necrosis factor alpha in patients with type 1 diabetes mellitus: A systematic review and meta-analysis.

Authors:  Yong-Chao Qiao; Yin-Ling Chen; Yan-Hong Pan; Fang Tian; Yan Xu; Xiao-Xi Zhang; Hai-Lu Zhao
Journal:  PLoS One       Date:  2017-04-20       Impact factor: 3.240

Review 4.  Cell Based Therapy for Type 1 Diabetes: Should We Take Hyperglycemia Into Account?

Authors:  Anna Grohová; Klára Dáňová; Radek Špíšek; Lenka Palová-Jelínková
Journal:  Front Immunol       Date:  2019-02-05       Impact factor: 7.561

Review 5.  Diabetic kidney disease in pediatric patients: A current review.

Authors:  Carmen Muntean; Iuliana Magdalena Starcea; Claudia Banescu
Journal:  World J Diabetes       Date:  2022-08-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.